SCPSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:18):

Stats
本日の出来高	943.00
平均出来高	1 281.00
時価総額	46 293.00
EPS	$-0.0658 ( 2023-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-23	Greenspan Ira Scott	Sell	3 000 000	W Warrants
2021-11-23	Lamstein Joshua R	Sell	3 000 000	W Warrants
2021-06-01	Hopper Paul	Buy	6 333	Common Stock
2020-12-15	Hopper Paul	Buy	0	Common Stock
2020-12-15	Hopper Paul	Sell	0	Common Stock

INSIDER POWER
0.00
Last 55 transactions
Buy: 2 180 518 \| Sell: 6 965 870

Scopus Biopharma Inc. 相関

10 最も正の相関
KTTA	0.932
ISPO	0.915
UTME	0.91
SMIT	0.91
MTP	0.909
CREG	0.908
NCBS	0.906
HOL	0.905
NKTX	0.904
SWVL	0.902

10 最も負の相関
GDNR	-0.933
AMYT	-0.924
NWLI	-0.913
BRAC	-0.911
EMLD	-0.91
BTWN	-0.91
CDZI	-0.909
AVAC	-0.909
PROF	-0.908
EXAS	-0.908

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Scopus Biopharma Inc. 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.550

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.550

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.02

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Scopus Biopharma Inc.

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.